INDV

Indivior Pharmaceuticals, Inc.

$40.50 -0.80 (-1.94%) At close · Jul 10

Market Cap

$4.94B

121,922,058

Up next

Next earnings call

Aug 3, 2026 Est · unconfirmed · in 3 wks

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Apr 30, 2026

AI Brief

TL;DR.

Bullish

Bearish

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating blended score · not investment advice

Overall

Buy

SellHoldBuy

Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Moderate

Market backdrop VIX 15 · calm Equity put/call 0.55

Technical

price trend

Buy

50 / 200-day cross No cross

Price vs 200-day avg +22%

above

Price vs 50-day avg +5%

above

RSI (14) 58

neutral

MACD trend Negative

52-week position 92%

near high

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Very Strong

1-month return +6%

trailing

6-month return +23%

trailing

YTD return +13%

this year

Relative strength +14%

vs S&P · 6-mo

Sentiment

smart money

Neutral

Trend (MA cross) No cross

50d $38 › 200d $33 — 50d above 200d

Institutional flow Accumulating

11 of 290 funds reported for Jun 30 · net +1.6M sh shares · +4 new

Insider flow Distributing

Net -$2.1M over 90 days · 100% sells

Short interest Falling

8.84% of float · ▼ -9.0% MoM · 4.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

290 holders — 13F breadth

Squeeze score 69

elevated · 0–100

Fundamentals

Strong

Revenue growth +4%

Y/Y

Gross margin 80%

contracting

EPS growth +3180%

Y/Y

Free cash flow $-93.0M

Valuation P/E 20.8

below peers

Balance sheet $124.0M

net debt

Quant / Vol

risk profile

Moderate

Volatility 39%

annualized · 1-yr

Max drawdown −21%

past year

ATR 3.5%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record what management promised — and delivered

Latest guidance · from the 8-K filed Apr 30, 2026

Net Revenue · Full-year 2026 Initiated $1.22B – $1.29B

prior FY $1.24B midpoint +0.9% Y/Y

Total SUBLOCADE Net Revenue · Full-year 2026 $950M – $990M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy

1 · 3 · 3

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

+22% Bullish

Price vs 50-day avg

+5% Bullish

RSI (14)

58 Neutral

MACD trend

Negative Bearish

52-week position

92% Bullish

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 2 of 6

Trend (MA cross) No cross

50d $38 › 200d $33 — 50d above 200d

Institutional flow Accumulating

11 of 290 funds reported for Jun 30 · net +1.6M sh shares · +4 new

Insider flow Distributing

Net -$2.1M over 90 days · 100% sells

Short interest Falling

8.84% of float · ▼ -9.0% MoM · 4.7 days cover

Volume signal Normal

Volume near normal

Institution breadth Steady

290 holders — 13F breadth

Price context

position in its 52-week range

52-wk low $15 Now $41 · 92% 52-wk high $43

vs 200-day avg +22% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings

Metric	Latest	Period	YoY
Average price of shares repurchased	$31.45	Q1 2026	—
Shares repurchased	3,974,153	Q1 2026	—
SUBLOCADE new patient starts	31,800	Q1 2026	—
active HCPs prescribing a second dose	23%	Q1 2026 call	—
active SUBLOCADE prescribers growth	19%	Q1 2026 call	—
adjusted EBITDA non-GAAP	$164M	Q1 2026 call	—
adjusted EBITDA growth non-GAAP	112%	Q1 2026 call	—
adjusted EBITDA margin improvement non-GAAP	23%	Q1 2026 call	—
convertible notes issued	$500M	Q1 2026 call	—
cumulative SUBLOCADE patients prescribed since launch	500,000	Q1 2026 call	—
Find a SUBLOCADE Treatment Provider searches	30,000	Q1 2026 call	—
HCPs treating five or more patients growth	20%	Q1 2026 call	—
new CRM enrollments per month	1,200	Q1 2026 call	—
new patient starts	31,800	Q1 2026 call	—
new patient starts growth	29%	Q1 2026 call	—
new patients receiving accelerated second dose	9%	Q1 2026 call	—
remaining share repurchase program authorization	$270M	Q1 2026 call	—
share repurchase average price	$31.45	Q1 2026 call	—
SUBLOCADE dispense unit growth	20%	Q1 2026 call	—
SUBLOCADE patients treated over last 12 months	191,600	Q1 2026 call	—
SUBLOCADE total category share of LAIs	76%	Q1 2026 call	—
total engaged consumers since launch	8,300	Q1 2026 call	—
U.S. SUBLOCADE dispense unit volume growth	7%	FY 2025	—

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Drug Manufacturers - Specialty & Generic — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
INDV Indivior Pharmaceuticals, Inc. this stock	$4.94B	+12.9%	+4.3%	20.8	8.8%
TAK Takeda Pharmaceutical Co Ltd	$52.88B	+6.2%	—	—	0.2%
GALDY Galderma Group AG/ADR	$50.15B	+3.2%	—	—	0.0%
JHPCY Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR	$45.13B	—	—	—	0.0%
HLN Haleon plc	$42.98B	-3.5%	—	—	0.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

294

% held: 99.9%
Reported: 11 of 290
Top holder: BlackRock, Inc.

Held Float

View

Held by Funds

Fund positions

294

View

Short & Settlement

Short Interest Falling

Shares short

10.8M

Days to cover: 4.7d
Change: -1.1M sh

View

Short Volume

Short vol %

69%

As of: Jul 10, 2026

Short Total

View

Fails to Deliver

FTD shares

14.1K

Value: $529.3K
As of: Jun 8, 2026

View

Off-Exchange

Off-exchange %

56.8%

Week of: May 4, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$2.1M

Buyers / Sellers: 0 / 2

Buyers Sellers

View

Financials

Revenue (FY)

$1.2B

Net income (FY): $210.0M
EPS diluted: $1.64

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Jun 30, 2026
This year: 13

View

Proposed Sales

Value

$764.6K

Shares: 18.6K
Filed: Jul 10, 2026

View

Earnings & Events

Earnings Calls

Last call

Jun 3, 2026

View

Performance

	5D	20D	120D	MTD	YTD
INDV	+1.8%	+6.3%	+23.2%	-1.3%	+12.9%
SPY	+1.4%	+4.1%	+9.1%	+1.1%	+10.7%
vs SPY	+0.4%	+2.3%	+14.1%	-2.4%	+2.2%

Key facts CIK 1625297 CUSIP 45579U109 13F (30d) 11 filings 11 filers Visit website Investor relations

INDV

Price & Indicators

Technicals

Key metrics

Versus peers

At a glance

Performance